公开(公告)号：US20150125463A1

公开(公告)日：2015-05-07

申请号：US14400667

申请日：2013-05-13

Applicant: Bristol-Myers Squibb Company

Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok Kumar Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/574 ,  C07K16/18

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52 ,  Y02A50/41 ,  Y02A50/412

Abstract: The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Abstract translation: 本公开提供了一种用于癌症患者的免疫治疗的方法，包括向患者施用抑制PD-1 / PD-L1信号传导途径的信号传导的Ab，或该抗体与抗CTLA-4Ab的组合。 本公开还提供了一种用于癌症患者的免疫治疗的方法，包括选择作为免疫治疗的合适候选者的患者，该评估基于来自表达细胞表面上的PD-L1的患者的来自患者的测试组织样品中细胞的比例超过 预定阈值水平，以及对所选择的受试者施用抗PD-1Ab。 本公开另外提供了与FFPE组织样品中的细胞表面表达的PD-L1抗原特异性结合的兔mAb，以及使用所提供的抗PD-L1抗体评估FFPE组织中的细胞表面表达的自动化IHC方法。

公开(公告)号：US09856320B2

公开(公告)日：2018-01-02

申请号：US14400667

申请日：2013-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok Kumar Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/76 ,  G01N33/57492 ,  G01N2333/70596 ,  G01N2800/52 ,  Y02A50/41 ,  Y02A50/412

Abstract: The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.